The pharma sector is often called India’s “sunrise industry” – it not only meets domestic healthcare needs but also supplies medicines to the world. For investors, this sector has delivered resilience during crises (like Covid-19) and continues to show strong long-term growth potential.

That’s where Pharma Mutual Funds come in. These are sectoral funds that invest in pharmaceutical, healthcare, and allied companies, giving you exposure to one of India’s most promising industries.
But are they right for your Portfolio? Let’s explore.
Pharma Mutual Funds are sectoral Equity Funds that invest primarily in companies from:
Since they are sector-specific, they carry higher risk than Diversified Funds, but also offer the chance to capture outsized gains when the sector outperforms.
Here’s why the Indian pharma industry is considered a strong bet:
In short: Pharma funds allow you to benefit from both domestic consumption growth and global demand for cost-effective drugs.
Talk to our investment specialist
Fund Selection Methodology used to find 10 funds
Fund NAV Net Assets (Cr) 3 MO (%) 6 MO (%) 1 YR (%) 3 YR (%) 5 YR (%) 2024 (%) TATA India Pharma & Healthcare Fund Growth ₹28.6301
↓ -0.38 ₹1,311 -8 -6.8 -5.1 19.7 13.9 -4.9 Nippon India Pharma Fund Growth ₹486.042
↓ -6.03 ₹8,265 -5.8 -7 -2.4 19.8 14.1 -3.3 UTI Healthcare Fund Growth ₹269.179
↓ -2.84 ₹1,102 -8.2 -8.7 -3.7 22 14.1 -3.1 SBI Healthcare Opportunities Fund Growth ₹406.267
↑ 4.15 ₹3,989 -7.8 -6.8 -2 22.5 15.5 -3.5 Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 23 Jan 26 Research Highlights & Commentary of 4 Funds showcased
Commentary TATA India Pharma & Healthcare Fund Nippon India Pharma Fund UTI Healthcare Fund SBI Healthcare Opportunities Fund Point 1 Lower mid AUM (₹1,311 Cr). Highest AUM (₹8,265 Cr). Bottom quartile AUM (₹1,102 Cr). Upper mid AUM (₹3,989 Cr). Point 2 Established history (10+ yrs). Established history (21+ yrs). Oldest track record among peers (26 yrs). Established history (21+ yrs). Point 3 Not Rated. Top rated. Rating: 1★ (lower mid). Rating: 2★ (upper mid). Point 4 Risk profile: High. Risk profile: High. Risk profile: High. Risk profile: High. Point 5 5Y return: 13.88% (bottom quartile). 5Y return: 14.12% (upper mid). 5Y return: 14.07% (lower mid). 5Y return: 15.52% (top quartile). Point 6 3Y return: 19.70% (bottom quartile). 3Y return: 19.75% (lower mid). 3Y return: 21.99% (upper mid). 3Y return: 22.50% (top quartile). Point 7 1Y return: -5.10% (bottom quartile). 1Y return: -2.42% (upper mid). 1Y return: -3.70% (lower mid). 1Y return: -2.03% (top quartile). Point 8 Alpha: -2.96 (bottom quartile). Alpha: -1.59 (upper mid). Alpha: -0.86 (top quartile). Alpha: -2.26 (lower mid). Point 9 Sharpe: -0.58 (lower mid). Sharpe: -0.52 (upper mid). Sharpe: -0.48 (top quartile). Sharpe: -0.58 (bottom quartile). Point 10 Information ratio: -0.13 (top quartile). Information ratio: -0.79 (bottom quartile). Information ratio: -0.16 (upper mid). Information ratio: -0.22 (lower mid). TATA India Pharma & Healthcare Fund
Nippon India Pharma Fund
UTI Healthcare Fund
SBI Healthcare Opportunities Fund
All the funds mentioned above are ideal, we are giving you detailed analysis of 3 funds.
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. Research Highlights for TATA India Pharma & Healthcare Fund Below is the key information for TATA India Pharma & Healthcare Fund Returns up to 1 year are on The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Research Highlights for Nippon India Pharma Fund Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on (Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. Research Highlights for UTI Healthcare Fund Below is the key information for UTI Healthcare Fund Returns up to 1 year are on (Erstwhile SBI Pharma Fund) To provide the investors maximum growth opportunity through equity
investments in stocks of growth oriented sectors of the economy. Research Highlights for SBI Healthcare Opportunities Fund Below is the key information for SBI Healthcare Opportunities Fund Returns up to 1 year are on 1. TATA India Pharma & Healthcare Fund
TATA India Pharma & Healthcare Fund
Growth Launch Date 28 Dec 15 NAV (23 Jan 26) ₹28.6301 ↓ -0.38 (-1.31 %) Net Assets (Cr) ₹1,311 on 31 Dec 25 Category Equity - Sectoral AMC Tata Asset Management Limited Rating Risk High Expense Ratio 2.17 Sharpe Ratio -0.58 Information Ratio -0.13 Alpha Ratio -2.96 Min Investment 5,000 Min SIP Investment 150 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Dec 20 ₹10,000 31 Dec 21 ₹11,907 31 Dec 22 ₹10,949 31 Dec 23 ₹14,954 31 Dec 24 ₹20,996 31 Dec 25 ₹19,963 Returns for TATA India Pharma & Healthcare Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 23 Jan 26 Duration Returns 1 Month -5.5% 3 Month -8% 6 Month -6.8% 1 Year -5.1% 3 Year 19.7% 5 Year 13.9% 10 Year 15 Year Since launch 11% Historical performance (Yearly) on absolute basis
Year Returns 2024 -4.9% 2023 40.4% 2022 36.6% 2021 -8% 2020 19.1% 2019 64.4% 2018 5.5% 2017 -2.6% 2016 4.7% 2015 -14.7% Fund Manager information for TATA India Pharma & Healthcare Fund
Name Since Tenure Rajat Srivastava 16 Sep 24 1.29 Yr. Data below for TATA India Pharma & Healthcare Fund as on 31 Dec 25
Equity Sector Allocation
Sector Value Health Care 95% Basic Materials 3.68% Asset Allocation
Asset Class Value Cash 1.31% Equity 98.69% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMA8% ₹103 Cr 600,722
↑ 34,367 Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Jul 25 | MAXHEALTH6% ₹77 Cr 736,671
↑ 85,656 Abbott India Ltd (Healthcare)
Equity, Since 30 Sep 25 | ABBOTINDIA5% ₹72 Cr 24,756
↑ 2,310 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB5% ₹66 Cr 102,707
↑ 38,606 HealthCare Global Enterprises Ltd (Healthcare)
Equity, Since 31 Dec 18 | HCG5% ₹63 Cr 958,575
↑ 19,001 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSP5% ₹62 Cr 88,528 Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | 5000874% ₹54 Cr 359,240
↑ 13,156 Rainbow Childrens Medicare Ltd (Healthcare)
Equity, Since 31 Jul 25 | 5435244% ₹49 Cr 374,328 Ipca Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 16 | 5244944% ₹49 Cr 343,870
↓ -24,011 J.B. Chemicals & Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Oct 25 | JBCHEPHARM4% ₹46 Cr 253,705 2. Nippon India Pharma Fund
Nippon India Pharma Fund
Growth Launch Date 5 Jun 04 NAV (23 Jan 26) ₹486.042 ↓ -6.03 (-1.23 %) Net Assets (Cr) ₹8,265 on 31 Dec 25 Category Equity - Sectoral AMC Nippon Life Asset Management Ltd. Rating ☆☆ Risk High Expense Ratio 1.81 Sharpe Ratio -0.52 Information Ratio -0.79 Alpha Ratio -1.59 Min Investment 5,000 Min SIP Investment 100 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Dec 20 ₹10,000 31 Dec 21 ₹12,393 31 Dec 22 ₹11,166 31 Dec 23 ₹15,538 31 Dec 24 ₹20,826 31 Dec 25 ₹20,130 Returns for Nippon India Pharma Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 23 Jan 26 Duration Returns 1 Month -5% 3 Month -5.8% 6 Month -7% 1 Year -2.4% 3 Year 19.8% 5 Year 14.1% 10 Year 15 Year Since launch 19.7% Historical performance (Yearly) on absolute basis
Year Returns 2024 -3.3% 2023 34% 2022 39.2% 2021 -9.9% 2020 23.9% 2019 66.4% 2018 1.7% 2017 3.6% 2016 7.6% 2015 -10.6% Fund Manager information for Nippon India Pharma Fund
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 20.77 Yr. Kinjal Desai 25 May 18 7.61 Yr. Lokesh Maru 5 Sep 25 0.32 Yr. Divya Sharma 5 Sep 25 0.32 Yr. Data below for Nippon India Pharma Fund as on 31 Dec 25
Equity Sector Allocation
Sector Value Health Care 97.37% Asset Allocation
Asset Class Value Cash 2.63% Equity 97.37% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA13% ₹1,076 Cr 6,256,349 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 5002577% ₹608 Cr 2,883,991
↓ -200,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB7% ₹544 Cr 850,754
↓ -50,000 Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 5000876% ₹528 Cr 3,495,054 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY6% ₹498 Cr 3,916,074 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP6% ₹457 Cr 648,795 Vijaya Diagnostic Centre Ltd (Healthcare)
Equity, Since 30 Sep 21 | 5433504% ₹306 Cr 2,886,684 Medplus Health Services Ltd (Healthcare)
Equity, Since 30 Nov 22 | 5434274% ₹293 Cr 3,627,277 Ajanta Pharma Ltd (Healthcare)
Equity, Since 30 Apr 22 | 5323313% ₹266 Cr 959,323 Sai Life Sciences Ltd (Healthcare)
Equity, Since 31 Dec 24 | SAILIFE3% ₹232 Cr 2,555,745 3. UTI Healthcare Fund
UTI Healthcare Fund
Growth Launch Date 28 Jun 99 NAV (23 Jan 26) ₹269.179 ↓ -2.84 (-1.04 %) Net Assets (Cr) ₹1,102 on 31 Dec 25 Category Equity - Sectoral AMC UTI Asset Management Company Ltd Rating ☆ Risk High Expense Ratio 2.26 Sharpe Ratio -0.48 Information Ratio -0.16 Alpha Ratio -0.86 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Dec 20 ₹10,000 31 Dec 21 ₹11,908 31 Dec 22 ₹10,441 31 Dec 23 ₹14,430 31 Dec 24 ₹20,614 31 Dec 25 ₹19,965 Returns for UTI Healthcare Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 23 Jan 26 Duration Returns 1 Month -6% 3 Month -8.2% 6 Month -8.7% 1 Year -3.7% 3 Year 22% 5 Year 14.1% 10 Year 15 Year Since launch 14.4% Historical performance (Yearly) on absolute basis
Year Returns 2024 -3.1% 2023 42.9% 2022 38.2% 2021 -12.3% 2020 19.1% 2019 67.4% 2018 1.2% 2017 -7.5% 2016 6.2% 2015 -9.7% Fund Manager information for UTI Healthcare Fund
Name Since Tenure Kamal Gada 2 May 22 3.67 Yr. Data below for UTI Healthcare Fund as on 31 Dec 25
Equity Sector Allocation
Sector Value Health Care 98.42% Basic Materials 0.98% Asset Allocation
Asset Class Value Cash 0.6% Equity 99.4% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA9% ₹103 Cr 600,000 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 5323317% ₹79 Cr 285,000 Lupin Ltd (Healthcare)
Equity, Since 28 Feb 25 | 5002576% ₹62 Cr 294,991
↓ -24,579 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | 5322964% ₹45 Cr 220,000
↓ -15,028 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND4% ₹40 Cr 230,000
↑ 8,838 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHL3% ₹38 Cr 66,803
↓ -211 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDY3% ₹38 Cr 299,461
↓ -35,539 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 5000873% ₹38 Cr 250,000 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEM3% ₹37 Cr 68,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSP3% ₹37 Cr 53,000 4. SBI Healthcare Opportunities Fund
SBI Healthcare Opportunities Fund
Growth Launch Date 31 Dec 04 NAV (22 Jan 26) ₹406.267 ↑ 4.15 (1.03 %) Net Assets (Cr) ₹3,989 on 31 Dec 25 Category Equity - Sectoral AMC SBI Funds Management Private Limited Rating ☆☆ Risk High Expense Ratio 1.97 Sharpe Ratio -0.58 Information Ratio -0.22 Alpha Ratio -2.26 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-15 Days (0.5%),15 Days and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Dec 20 ₹10,000 31 Dec 21 ₹12,015 31 Dec 22 ₹11,292 31 Dec 23 ₹15,609 31 Dec 24 ₹22,199 31 Dec 25 ₹21,423 Returns for SBI Healthcare Opportunities Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 23 Jan 26 Duration Returns 1 Month -4.5% 3 Month -7.8% 6 Month -6.8% 1 Year -2% 3 Year 22.5% 5 Year 15.5% 10 Year 15 Year Since launch 14.8% Historical performance (Yearly) on absolute basis
Year Returns 2024 -3.5% 2023 42.2% 2022 38.2% 2021 -6% 2020 20.1% 2019 65.8% 2018 -0.5% 2017 -9.9% 2016 2.1% 2015 -14% Fund Manager information for SBI Healthcare Opportunities Fund
Name Since Tenure Tanmaya Desai 1 Jun 11 14.6 Yr. Data below for SBI Healthcare Opportunities Fund as on 31 Dec 25
Equity Sector Allocation
Sector Value Health Care 89.74% Basic Materials 6.86% Asset Allocation
Asset Class Value Cash 3.33% Equity 96.6% Debt 0.07% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA12% ₹464 Cr 2,700,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB7% ₹281 Cr 440,000 Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | MAXHEALTH5% ₹209 Cr 2,000,000 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 23 | 5002574% ₹177 Cr 840,000 Laurus Labs Ltd (Healthcare)
Equity, Since 31 Aug 23 | 5402224% ₹155 Cr 1,400,000 Torrent Pharmaceuticals Ltd (Healthcare)
Equity, Since 30 Jun 21 | TORNTPHARM4% ₹154 Cr 400,000 Acutaas Chemicals Ltd (Basic Materials)
Equity, Since 30 Jun 24 | 5433494% ₹153 Cr 900,000 Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | 5000874% ₹151 Cr 1,000,000
↓ -200,000 Lonza Group Ltd ADR (Healthcare)
Equity, Since 31 Jan 24 | LZAGY4% ₹145 Cr 240,000
↓ -30,000 Biocon Ltd (Healthcare)
Equity, Since 30 Nov 24 | BIOCON3% ₹126 Cr 3,200,000
Pharma Mutual Funds generally track or take cues from the Nifty Pharma Index.
Key Highlights:
To more about index can be read on official website Nifty Pharma Index Document
Pharma funds are not for everyone. They are suitable if you are:
Not suitable for:
Here’s what most articles miss, but you should keep in mind:
Globally, populations are ageing, particularly in developed countries. Indian companies are well-placed to serve this demand.
Pharma is no longer just about medicines. Healthcare funds now capture hospitals, diagnostics, and preventive care businesses – expanding growth scope.
One USFDA ban can wipe out a stock’s value overnight. That’s why pharma funds spread risk across multiple companies.
The pandemic proved how pharma can outperform when healthcare demand spikes – but it also showed the need to stay cautious about hype-driven rallies.
Open Free Investment Account for Lifetime at Fincash.com.
Complete your Registration and KYC Process
Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest!
India’s healthcare system is unique — while public hospitals account for only 30% of total hospital beds, the rest come from the private sector. This means the majority of patients depend on private care, which directly drives higher demand for medicines, diagnostics, and health insurance.
For pharma investors, this is critical. Unlike other industries, demand here is not cyclical — healthcare is a necessity. The more patients turn to private care, the more they rely on affordable medicines, making pharmaceutical companies long-term revenue generators.
The imbalance also highlights another important point: out-of-pocket expenditure in India is one of the highest in the world, around 48–50% of total healthcare spend. This forces households to prioritise low-cost drugs, generic medicines, and insurance-backed treatments — exactly the segments where Indian pharma companies have a competitive advantage.
Add to this the rise of medical tourism (expected to reach $13 billion+ by 2026), demand for speciality care in tier-2 cities, and a growing middle class that spends more on preventive healthcare. All of these trends ensure steady tailwinds for pharma companies and, by extension, pharma mutual funds.
This trend explains why pharma mutual funds are seen as a defensive bet — they combine healthcare demand certainty with the growth potential of India’s expanding private medical sector. In other words, the gap between public and private healthcare isn’t just a social challenge — it’s an investment signal, and one that smart investors can capture through pharma-focused fund.
Pharma Mutual Funds give investors a chance to tap into one of India’s strongest industries – with global leadership in generics, a growing domestic market, and government support. However, these are high-risk, high-reward funds. Don’t allocate more than 10–15% of your portfolio to sectoral funds, and always combine them with diversified mutual funds for stability.
If you believe in the long-term growth of healthcare and India’s role as the “Pharmacy of the World,” pharma funds can be a smart addition to your portfolio.
A: Yes, since they are concentrated sector funds. Suitable only for those who can take high risk.
A: Diversified funds spread risk across sectors, pharma funds focus only on one. They can outperform in pharma bull runs but underperform otherwise.
A: At least 5 years. Short-term Investing in sector funds is not recommended.
A: Yes, SIPs help average out volatility in sectoral funds.
Please send list of funds which has the option of changing the sector of funds so that overall performance of mutual funds are always very good. Thanks and Regards
Are largecap is best investment on longterm